Elkedonia, a Franco-Belgian startup launched by Argobio and based on research from Sorbonne University, secured €11.25 million in seed funding to develop novel neuroplastogens for treatment-resistant depression and other neuropsychiatric disorders. These first-in-class molecules target Elk1, an intracellular protein involved in reward circuits and neuroplasticity, differentiating them from existing treatments like ketamine. The funding round was co-led by Kurma Partners, WE Life Sciences, and the French Tech Seed fund managed by Bpifrance, with participation from several other investors.
This development holds significant promise for addressing the substantial unmet need in depression treatment. Current antidepressants prove ineffective for approximately one-third of patients, highlighting the urgency for novel approaches. Elkedonia’s focus on restoring neuroplasticity without the side effects associated with psychedelics or ketamine derivatives represents a potentially transformative shift in the treatment landscape. This could offer new hope for millions suffering from treatment-resistant depression and other neuropsychiatric conditions, including young people, adolescents, and the elderly, for whom current options are often inadequate. Furthermore, the company’s parallel development of biomarkers suggests a move towards personalized medicine, potentially allowing for more effective patient selection and treatment monitoring.
The secured funding will be used to identify and optimize small molecule Elk1 inhibitors, as well as to further research and validate biomarkers. This multifaceted approach indicates a commitment to both drug development and personalized therapeutic strategies. The strong financial backing from a syndicate of leading life sciences investors, including prominent European venture capital firms and governmental funds, provides Elkedonia with the resources to advance its research and development efforts.
Elkedonia’s novel approach to tackling treatment-resistant depression has the potential to reshape the mental health landscape. The successful seed funding round allows the company to move forward with its research and development programs. The combined focus on a novel mechanism of action, a targeted patient population, and the development of biomarkers positions Elkedonia as a company to watch in the coming years as it progresses toward clinical trials and potentially brings much-needed relief to patients. The success of this endeavor could have significant implications for the broader mental health field, offering a new paradigm for the treatment of these debilitating conditions.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
